Page 10 - Pharmaceutical Firms

Alembic Pharma Q1FY25 results: Net profit increases 12% to Rs 135 cr

Alembic Pharmaceuticals on Thursday said its consolidated net profit increased by 12 per cent to Rs 135 crore for the first quarter ended on June 30, 2024. The drug firm had reported a net profit of Rs 121 crore for the April-June quarter of last fiscal. Total income increased to Rs 1,564 crore for the June quarter as against Rs 1,498 crore in the year-ago period, Alembic Pharmaceuticals said in a regulatory filing. "India branded business continues to work on improving the execution ability both in quality and scale," Alembic Pharmaceuticals MD Shaunak Amin said. The specialty and animal health segment witnessed robust growth, he added. "The USFDA conducted an audit at our formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18 per cent during the quarter," Amin said. Shares of the company ended 0.11 per cent down at Rs 1,218.65 apiece on the BSE.

Ola Electric's IPO subscribed 4.3 times; Akums Drugs shares gain 17%

Shares of Akums Drugs and Pharmaceuticals rose over 17 per cent during their trading debut on Tuesday

Back in biz: Equity investors turn aggressive on red-hot defensive stocks

Most of the rise in the defensive sector weightage in the index has so far been led by pharmaceutical manufacturers but FMCG and IT Services companies out-perform the broader market in July

Pharma firm Rubicon Research files draft papers for Rs 1,085-cr IPO

Pharmaceutical formulation company Rubicon Research Ltd has filed draft papers with capital markets regulator Sebi to garner Rs 1,085 crore through an initial share sale. The company's Initial Public Offering (IPO) is a combination of a fresh issue of equity shares worth Rs 500 crore and an Offer For Sale (OFS) of shares valued at Rs 585 crore by promoter, General Atlantic Singapore RR Pte Limited, according to the Draft Red Herring Prospectus (DRHP) filed on Wednesday. At present, General Atlantic owns over 57 per cent stake in Rubicon Research. The company proposes to utilise proceeds from the fresh issue to the tune of Rs 310 crore for payment of debt. Also, funds will be used for supporting inorganic growth through unidentified acquisitions as well as other strategic initiatives and general corporate purposes. Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality produ

Akums Drugs and Pharma's IPO gets fully-subscribed on Day 1 of offer

The initial public offer of Akums Drugs and Pharmaceuticals got fully-subscribed on the first day of subscription on Tuesday. The Rs 1,875-crore initial share sale received bids for 2,07,92,684 shares, as against 1,51,62,239 shares on offer, translating to 1.37 times subscription, as per the NSE data. The issue will conclude on August 1. The quota for Retail Individual Investors (RIIs) received 3.35 times subscription, while the Non Institutional Investors part got subscribed 1.96 times. The portion for qualified institutional buyers (QIBs) received 43 per cent subscription. The IPO is a combination of a fresh issue of equity shares worth Rs 680 crore and an offer-for-sale (OFS) of 1.73 crore shares valued at Rs 1,177 crore at the upper-end of the price band by promoters and an existing investor. Those selling shares in the OFS are Sanjeev Jain, Sandeep Jain and Ruby QC Investment Holdings Pte Ltd. The public issue has a price range of Rs 646 to Rs 679 per share Akums Drugs and

Ajanta Pharma Q1 results: PAT up 18% to Rs 246 cr on robust sales

Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets. The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing. The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter. The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal. Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE.

USFDA scrutiny delays generic drug approvals for major Indian pharma firms

Big Pharma companies Cipla, Sun Pharma, Aurobindo Pharma, Dr Reddy's, and Lupin face intense scrutiny from the US Food and Drug Administration (USFDA)

BSV portfolio can touch Rs 5K cr in 3-4 yrs: Mankind Pharma's Rajeev Juneja

'We don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity'

Dr Reddy's Laboratories Q1 result: Net profit dips 0.90%, revenue up 13.88%

DRL's growth was primarily driven by the robust performance of the global generics business, particularly in North America and India

Mankind Pharma to lead in Indian women's health market after BSV deal

Deal opens doors to overseas markets with low competition

Sun Pharma Q1 Preview: R&D spends to hit margins; profits may rise 10%

Brokerages expect a satisfactory quarter for Sun Pharma giant with a steady growth in the topline as well as bottomline on a year-on-year (YoY) basis, however, sequentially the bottomline may get hit

Mankind Pharma frontrunner to acquire Bharat Serums in $1.5 bn deal

Mankind Pharma rose as much as 1.2 per cent following Thursday's Bloomberg News report. The shares are up about 6.5 per cent this year and 10 per cent in the past 12 months

Australia's Mayne Pharma sues Sun Pharma over patent infringement

In the lawsuit filed at the United States District Court for New Jersey, Mayne Pharma accused its rival of violating all 20 Orange Book-listed patents linked to IMVEXXY

Zydus Lifesciences gets Mexican authority nod for cancer remedy biosimilar

Zydus Lifesciences Ltd on Monday said it has received marketing approval from the Mexican regulatory authority for its biosimilar product -- Bhava, used in the treatment of certain types of cancers. Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval for Bhava, a Bevacizumab biosimilar and it will be marketed in different strengths of 100 mg/4 ml and 400 mg/16 ml, Zydus Lifesciences said in a regulatory filing. Bhava is used in the treatment of metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, advanced and/or metastatic renal cell carcinoma and ovarian cancer patients, it added. Zydus Managing Director, Sharvil Patel said the approval granted by COFEPRIS is the company's first biosimilars for patients in Latin America. "To bring in greater access and affordability to patients battling critical ailments, we have been developing a pipelin

Aurobindo Pharma board approves share buyback plan worth Rs 750 cr

Aurobindo Pharma on Thursday said its board has approved a share buyback plan of up to Rs 750 crore. The company's board has approved the buyback of up to 51,36,986 shares representing up to 0.88 per cent of the total paid-up equity share capital, Aurobindo Pharma said in a regulatory filing. The company will buy the shares at Rs 1,460 apiece for an aggregate amount of up to Rs 750 crore, it added. The drug firm said July 30 has been fixed as the record date for the Rs 750-crore share buyback scheme through the tender offer route. At the end of June 30, the company promoters owned 51.8 per cent stake, while foreign institutional investors (FIIs) and mutual funds owned 16.73 per cent and 19.17 per cent respectively. Shares of Aurobindo Pharma were trading 2.83 per cent down at Rs 1,332.90 apiece on the BSE.

Mankind Pharma and EQT compete to acquire BSV Group for Rs 14,000 crore

Advent International, the private equity firm currently owning BSV, appointed JP Morgan and Jefferies to facilitate the sale of the biopharma firm

Pharma groups criticise plan to shift nutraceuticals under drug authority

Pharmaceutical industry is urging government to halt the transfer of nutraceutical oversight from FSSAI to the drug regulatory authority, citing potential market impact

Subhash Dandekar: The man who brought colour to the Indian masses

He took over Camlin from his father, Digambar Dandekar, who started the company in 1931 as an ink manufacturer and then also began selling office stationery

Veerhealth Care expects Rs 100 crore revenue in upcoming 2-3 years

Veerhealth Care on Monday said it is expecting to reach revenue of Rs 100 crore in the next 2 to 3 years. In a statement, the company said it has executed and delivered an export order valued at USD 50,000 (about Rs 41.50 lakh). Additionally, another export order valued at USD 197,793 (approximately Rs 165 lakh) is scheduled to be fully executed and delivered by the end of July. According to the statement, the company has also received an additional export order worth USD 106,673 (about Rs 89 lakh) from top US Institutional Supplier. The order will be executed within three months, as stipulated by the terms of the purchase agreement. Further, it stated that it is expecting monthly repeat orders from the same top US Institutional Supplier. In addition to this, the company said it is renovating its existing plant in Vapi, Gujarat, to set up a bigger plant which will be US FDA & WHO-compliant. In February 2024, the company has announced its expansion plans with a proposed investmen

Q1 results preview: Niche US products, domestic growth may boost pharma biz

Brokerages expect aggregate sales growth of 11 per cent, and 21 per cent earnings growth during this period